Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Timmerman

Showing results (211-220 of 229) with videos related to

Pageof 23
Sort By:
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Cancer Discovery|November 23, 2022
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin LymphomaSarah M Larson, Christopher M Walthers, Brenda Ji, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Lancet (London, England)|February 19, 2008
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trialMarc Gh Besselink, Hjalmar C van Santvoort, Erik Buskens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialPhilippe Armand, Arnon Nagler, Edie A Weller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Active idiotypic vaccination versus control immunotherapy for follicular lymphomaRonald Levy, Kristen N Ganjoo, John P Leonard, et al.
Pageof 23

Showing results (211-220 of 229) with videos related to

Sort By:
Pageof 23
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Cancer Discovery|November 23, 2022
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin LymphomaSarah M Larson, Christopher M Walthers, Brenda Ji, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Lancet (London, England)|February 19, 2008
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trialMarc Gh Besselink, Hjalmar C van Santvoort, Erik Buskens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialPhilippe Armand, Arnon Nagler, Edie A Weller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Active idiotypic vaccination versus control immunotherapy for follicular lymphomaRonald Levy, Kristen N Ganjoo, John P Leonard, et al.
Pageof 23